This informal CPD article ‘Why Some Vaccines Protect for a Lifetime While Others Need a Booster’ was provided by Cima Care, who offer extensive training in vaccination and public health, advancing global health initiatives.
A single dose of yellow fever vaccine can protect a traveller for life. A single dose of this year's influenza vaccine may lose much of its effect within months. Both work through the same immune system and the same antibody-producing cells, yet they leave behind different legacies of protection. This gap between vaccines that provide lifelong protection and vaccines whose protection fades within months sits at the heart of vaccine science. It is assessed through new tools that let researchers watch immune memory form inside human lymph nodes, providing evidence-based explanation. [1 & 2]
The Cells That Remember
Two cell populations do the work of "remembering" a vaccine. Long-lived plasma cells settle permanently in the bone marrow, quietly manufacturing antibodies for years or decades without additional exposure to the germ. Memory B cells circulate in the blood on standby, ready to reactivate and produce a quick antibody surge if the same pathogen reappears. [3] Both are produced in germinal centres, temporary "proving grounds" inside lymph nodes where immune cells compete and refine their antibody genes over several weeks so that only the strongest survive. How intensely and for how long this process runs are now understood to be the main factor deciding how long the resulting protection lasts. [4]
A Decade Versus Almost Forever
The scale of the difference between vaccines is not subtle. One study followed adults for up to 26 years, tracking how their antibody levels against various infections and vaccines declined over time. The estimated "half-life" of protection, the time taken for antibody levels to fall by half, ranged enormously: roughly a decade for tetanus and diphtheria vaccines, compared with a half-life measured in centuries, effectively permanent, for measles and mumps. [6]
One Shot for Life
Vaccines made from a live, weakened virus, such as those for yellow fever and measles, sit at the permanent end of this spectrum because they mimic a real infection: the weakened virus still replicates briefly in the body, producing a prolonged, stronger wave of antigen than a single injection ever could. [3] On this basis, an international expert advisory group concluded in 2014 that a single dose of yellow fever vaccine gives sustained, lifelong protection, and international health regulations were formally amended in 2016 to remove any requirement for booster doses. [7 & 8] A 2025 study of Japanese travellers vaccinated years earlier confirmed the decision, finding protective antibody levels still present well over a decade after a single injection. [9] Measles tells a similar story, which is why outbreaks trace overwhelmingly to unvaccinated groups rather than to fading immunity among the vaccinated. [10] Not every child responds fully to a single dose. Around 5–10% fail to develop protection after their first dose of the measles–mumps–rubella (MMR) vaccine, so a second dose catches these non-responders. It raises overall population protection to about 97%. [11 & 12]
Why Boosters Exist
Not every vaccine can mimic natural infection this closely, and the whooping cough vaccine shows what happens when it does not. Older whole-cell pertussis vaccines, made from entire killed bacteria, induced broader and more durable immunity. The newer acellular vaccines, which use only a few purified proteins from the bacterium, are gentler, but their protection wanes faster, a pattern that researchers link to the renewed circulation of whooping cough in several highly vaccinated countries. [13]
Toxoid vaccines, such as those for tetanus and diphtheria, are made from inactivated toxins that cannot replicate at all, so they typically support protection for only 11 to 19 years, consistent with the familiar 10-year booster schedule. [14 & 15] Influenza vaccines face a double challenge: protective memory can weaken like any non-live vaccine, but the virus itself also keeps changing. Small genetic changes in its surface proteins, called antigenic drift, let new strains partly escape existing immunity; our immune system tends to 'lock in' on the first flu strain we met as children, focusing later responses on that early pattern. That childhood imprint can make our protection narrower than we expect against different strains we meet later in life. [16 & 17] The result is durable memory to an increasingly out-of-date target, which is why annual reformulation, rather than durability engineering, remains influenza's central challenge. [18]
mRNA COVID-19 vaccines
The COVID Vaccine Lesson
mRNA COVID‑19 vaccines let scientists watch the body's training process in real time. By repeatedly checking the same lymph nodes in volunteers, they found that these vaccines keep the immune system's training or germinal centre active for at least six months, one of the longest‑lasting training responses ever seen in people, and ongoing studies are now teasing out which parts of the vaccine are responsible for this effect." [4, 19 & 20]
After COVID‑19 infection or vaccination, special immune cells called T cells learn to spot the virus and infected cells. They recognise many different parts of the virus, not just one, so their memory stays useful even when the virus changes. These changes are called variants—new versions of the virus with small genetic differences. Because T‑cell memory covers many pieces of the virus and lasts a long time, it still works well against these new variants. It helps prevent severe illness and hospitalisation, even after antibody levels in the blood have gone down. [21]
Getting It Right Without a Live Virus
Two newer, non-live vaccines, those for human papillomavirus (HPV) and recombinant hepatitis B vaccines, show that strong, long-lasting protection is possible even without using a virus that reproduces in the body, as long as the target piece of the virus (the antigen) and the helper ingredients that promote the immune response (the adjuvant) are carefully designed. Human papillomavirus (HPV) vaccines have been followed for up to 14 years in one Nordic study and 10 years in a trial of a newer version, and in both cases antibody levels stayed high with no sign that protection was weakening over time. [22 & 23]
Hepatitis B vaccine is an even more instructive case: measurable antibody does fall over 20 to 30 years, yet immune memory persists independently in specialised B and T cells, so most vaccinated people still mount a rapid, protective antibody surge if re-exposed decades later, which is why global guidelines do not recommend routine boosters. [24] The broader lesson is that measuring antibody levels alone can seriously underestimate true protection, since memory cells often keep working long after visible antibody has faded. [25]
Engineering Longer-Lasting Protection
The most active area of vaccine research today is finding ways for older and newer vaccines to leave behind long‑term immune "memories" in the same way that live (weakened) vaccines do naturally. One important tool is a plant‑based helper ingredient called Matrix‑M, made from natural substances (saponins) in the bark of the soapbark tree. When Matrix‑M is added to non‑live, protein‑based vaccines, it sends a strong "alarm" signal in nearby lymph nodes, drawing in and activating immune cells so they train harder and remember longer, which makes these vaccines last more like live vaccines in the body. [26]
There are now two kinds of mRNA COVID‑19 vaccines. Conventional mRNA vaccines deliver a short‑lived set of genetic instructions: our cells read this message, make the spike protein for a while, and then the message breaks down, so protein production fades. Self‑amplifying mRNA vaccines add extra instructions that let this message copy itself inside our cells, so the body keeps making the spike protein antigen for longer even from a smaller starting dose. In a large 12‑month clinical trial, people who received a self‑amplifying mRNA booster had stronger immune responses and higher antibody levels one year later than people who received a conventional mRNA vaccine, showing that self‑amplifying mRNA can give longer‑lasting protection with less material. [27]
A third approach borrows from structural biology: nanoparticles displaying fragments from several virus strains at once are being designed to steer the immune system towards broader, cross-reactive protection rather than a single, narrow target. [28] None yet rivals the multi-decade memory of a live measles or yellow fever vaccine, but together they represent a serious attempt to reverse-engineer nature's most durable trick. [29]
Turning Knowledge into Everyday Protection
Understanding why immunity fades is only useful if it changes practice. Missed follow-up doses remain one of the most persistent, fixable gaps in immunisation programmes worldwide, and reminder and recall systems, including simple text-message reminders, are among the best-evidenced ways of closing that gap. [30 & 31] Real-time digital dashboards extend this to the population level by giving health workers clearer visibility into coverage gaps, while structured communication training has been shown to leave health workers more confident discussing vaccination with patients. [5 & 32]
We hope this article was helpful. For more information from Cima Care, please visit their CPD Member Directory page. Alternatively, you can go to the CPD Industry Hubs for more articles, courses and events relevant to your Continuing Professional Development requirements.
References
1- Schnyder JL, Hanna, Bache BE, Schaumburg F, Grobusch MP. Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis. The Lancet Global Health. 2024 Mar 1;12(3):e445–56.
2- Doyon-Plourde P, Przepiorkowski J, Young K, Zhao L, Sinilaite A. Intraseasonal waning immunity of seasonal influenza vaccine – A systematic review and meta-analysis. Vaccine [Internet]. 2023 Jun 16 [cited 2026 Jul 14]. Available from: https://www.sciencedirect.com/science/article/pii/S0264410X23007132
3- Emerging novel methodologies to understand and strategically target long-lived plasma cells in vaccine design to induce durable immunity. Front Immunol. 2025. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1680375/full
4- Kim W, Zhou JQ, Horvath SC, Schmitz AJ, Sturtz AJ, Lei T, et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature. 2022 Feb 15;604(7904):141–5.
5- WHO Regional Office for Europe. New WHO study shows health workers feel more confident to recommend COVID-19 vaccination following a training on patient communication [Internet]. Copenhagen: WHO/Europe; 2023.
6- Amanna IJ, Carlson NE, Slifka MK. Duration of Humoral Immunity to Common Viral and Vaccine Antigens. N Engl J Med. 2007;357(19):1903–1915. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa066092
7- WHO. Yellow fever [Internet]. Fact sheets. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/yellow-fever
8- WHO. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013 – recommendations. Vaccine [Internet]. 2015 Jan [cited 2026 Jul 15];33(1):76–7. Available from: https://pubmed.ncbi.nlm.nih.gov/24852721/
9- Fukushima S, Lim CK, Hamada A. A Single Dose of Yellow Fever Vaccine Provides Long-Term Immunity in Japanese Travelers. Vaccines. 2025;13(7):675. Available from: https://www.mdpi.com/2076-393X/13/7/675
10- Centers for Disease Control and Prevention. Measles Vaccination [Internet]. Measles (Rubeola). CDC; 2024 [cited 2026 Jul 15]. Available from: https://www.cdc.gov/measles/vaccines/index.html
11- Zapata K. An expert answers questions about the measles – UT Health San Antonio [Internet]. UT Health San Antonio. 2025 [cited 2026 Jul 15]. Available from: https://news.uthscsa.edu/an-expert-answers-questions-about-the-measles/
12- World Health Organization. Evidence for measles vaccine effectiveness: background to the WHO position paper on measles vaccines, April 2017 [Internet]. Geneva: WHO; 2017. Available from: https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/measles/measles-grad-effectiveness.pdf
13- Szwejser-Zawislak E, Wilk MM, Piszczek P, Krawczyk J, Wilczyńska D, Hozbor D. Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity. Vaccines. 2022 Dec 20;11(1):1.
14- World Health Organization. The immunological basis for immunization series. Module 3: Tetanus. Update 2018 [Internet]. Geneva: WHO; 2018 [cited 2026 Jul 15]. Available from: https://www.who.int/publications/i/item/9789241513616
15- Committee IMUVS, Stratton KR, Howe CJ, Johnston RB Jr. Diphtheria and Tetanus Toxoids [Internet]. National Academies Press (US); 1994 [cited 2026 Jul 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK236292/
16- Maurer DP, Vu M, Schmidt AG. Antigenic drift expands influenza viral escape pathways from recalled humoral immunity. Immunity [Internet]. 2025 Feb 28 [cited 2026 Jul 15];58(3):716–27. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1074761325000743
17- Sun J, Jo G, Troxell CA, Fu Y, Hoezl R, Lv H, et al. B cell imprinting in children impairs antibodies to the haemagglutinin stalk. Nature [Internet]. 2026 Mar 11 [cited 2026 Jul 15]. Available from: https://www.nature.com/articles/s41586-026-10248-6
18- Houser K, Subbarao K. Influenza vaccines: challenges and solutions. Cell Host & Microbe. 2015;17(3):295–300. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4362519/
19- Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature [Internet]. 2021 Jun 28 [cited 2026 Jul 15];596:1–5. Available from: https://www.nature.com/articles/s41586-021-03738-2
20- Castaño D, Bettini E, Kumar B, Chudnovskiy A, Siv A, Protti G, et al. Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses. Cell [Internet]. 2025 Dec [cited 2026 Jul 15];188(26):7461–80. Available from: https://www.cell.com/cell/fulltext/s0092-8674(25)01358-3#page-body-id
21- Wang L, Nicols A, Turtle L, Richter A, Duncan CJ, Dunachie SJ, et al. T cell immune memory after covid-19 and vaccination. BMJ Medicine [Internet]. 2023 Nov 1;2(1). Available from: https://bmjmedicine.bmj.com/content/2/1/e000468
22- Kjaer SK, Nygård M, Sundström K, Dillner J, Tryggvadottir L, Munk C, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. EClinicalMedicine. 2020 Jun;23:100401.
23- Restrepo J, Herrera T, Samakoses R, et al. Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety. Pediatrics. 2023;152(4):e2022060993. Available from: https://publications.aap.org/pediatrics/article/152/4/e2022060993/193886
24- Van Damme P, Dionne M, Leroux-Roels G, Van Der Meeren O, Di Paolo E, Salaun B, et al. Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults. Journal of Viral Hepatitis. 2019 Jun 2;26(9):1066–75.
25- Brooks BD, Beland A, Aguero G, Taylor N, Towne FD. Moving beyond Titers. Vaccines. 2022 Apr 26;10(5):683.
26- Stertman L, Palm AKE, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson SE, et al. The Matrix-M adjuvant: A critical component of vaccines for the 21st century. Human Vaccines & Immunotherapeutics [Internet]. 2023 Apr 27;19(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158541/
27- Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination [Internet]. Global Newsroom | CSL. 2024 [cited 2026 Jul 16]. Available from: https://newsroom.csl.com/2024-09-30-Self-Amplifying-mRNA-COVID-19-Vaccine-Demonstrates-Superior-Immune-Response-Compared-with-mRNA-Vaccine-at-12-Months-Post-Vaccination
28- Wang E, Cohen AA, Caldera LF, Keeffe JR, Rorick AV, Adia YM, et al. Designed mosaic nanoparticles enhance cross-reactive immune responses in mice. Cell [Internet]. 2025 Jan 1. Available from: https://www.cell.com/cell/fulltext/S0092-8674(24)01428-4
29- Srivastava S, Jayaswal N, Gupta P, Sridhar SB, Jaiswal P, Mohd T, et al. The Yellow Fever Vaccine Journey: Milestones and Future Directions. Vaccines [Internet]. 2026 Jan 5;14(1):65. Available from: https://www.mdpi.com/2076-393X/14/1/65
30- Jacobson Vann VL, Jacobson RM, Coyne-Beasley T, Asafu-Adjei JK, Szilagyi PG. Patient reminder and recall interventions to improve immunization rates. Cochrane Database Syst Rev. 2018;1(1):CD003941.
31- Louw GE, Hohlfeld ASJ, Kalan R, Engel ME. Mobile Phone Text Message Reminders to Improve Vaccination Uptake: A Systematic Review and Meta-Analysis. Vaccines (Basel). 2024;12(10):1151.
32- Tajudeen R, Fallah MP, Ojo J, Shaweno T, Mekbib MS, Mulugeta F, et al. COVID-19 vaccination data management and visualisation systems for improved decision-making: lessons learnt from the Africa CDC Saving Lives and Livelihoods programme. PLOS Digit Health. 2025.
